PMID- 21908714
OWN - NLM
STAT- MEDLINE
DCOM- 20120228
LR  - 20230608
IS  - 1530-6860 (Electronic)
IS  - 0892-6638 (Print)
IS  - 0892-6638 (Linking)
VI  - 25
IP  - 12
DP  - 2011 Dec
TI  - VCAM-1-targeted magnetic resonance imaging reveals subclinical disease in a mouse 
      model of multiple sclerosis.
PG  - 4415-22
LID - 10.1096/fj.11-183772 [doi]
AB  - Diagnosis of multiple sclerosis (MS) currently requires lesion identification by 
      gadolinium (Gd)-enhanced or T(2)-weighted magnetic resonance imaging (MRI). 
      However, these methods only identify late-stage pathology associated with 
      blood-brain barrier breakdown. There is a growing belief that more widespread, 
      but currently undetectable, pathology is present in the MS brain. We have 
      previously demonstrated that an anti-VCAM-1 antibody conjugated to microparticles 
      of iron oxide (VCAM-MPIO) enables in vivo detection of VCAM-1 by MRI. Here, in an 
      experimental autoimmune encephalomyelitis (EAE) mouse model of MS, we have shown 
      that presymptomatic lesions can be quantified using VCAM-MPIO when they are 
      undetectable by Gd-enhancing MRI. Moreover, in symptomatic animals VCAM-MPIO 
      binding was present in all regions showing Gd-DTPA enhancement and also in areas 
      of no Gd-DTPA enhancement, which were confirmed histologically to be regions of 
      leukocyte infiltration. VCAM-MPIO binding correlated significantly with 
      increasing disability. Negligible MPIO-induced contrast was found in either EAE 
      animals injected with an equivalent nontargeted contrast agent (IgG-MPIO) or in 
      control animals injected with the VCAM-MPIO. These findings describe a highly 
      sensitive molecular imaging tool that may enable detection of currently invisible 
      pathology in MS, thus accelerating diagnosis, guiding treatment, and enabling 
      quantitative disease assessment.
FAU - Serres, Sebastien
AU  - Serres S
AD  - Cancer Research UK/Medical Research Council Gray Institute for Radiation Oncology 
      and Biology, Department of Oncology, Churchill Hospital, Oxford, OX3 7LJ, UK.
FAU - Mardiguian, Silvy
AU  - Mardiguian S
FAU - Campbell, Sandra J
AU  - Campbell SJ
FAU - McAteer, Martina A
AU  - McAteer MA
FAU - Akhtar, Asim
AU  - Akhtar A
FAU - Krapitchev, Alexandre
AU  - Krapitchev A
FAU - Choudhury, Robin P
AU  - Choudhury RP
FAU - Anthony, Daniel C
AU  - Anthony DC
FAU - Sibson, Nicola R
AU  - Sibson NR
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
GR  - 088291/WT_/Wellcome Trust/United Kingdom
GR  - 090532/WT_/Wellcome Trust/United Kingdom
GR  - G0401438/MRC_/Medical Research Council/United Kingdom
PT  - Comparative Study
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110909
PL  - United States
TA  - FASEB J
JT  - FASEB journal : official publication of the Federation of American Societies for 
      Experimental Biology
JID - 8804484
RN  - 0 (Contrast Media)
RN  - 0 (Ferric Compounds)
RN  - 0 (Vascular Cell Adhesion Molecule-1)
RN  - 1K09F3G675 (ferric oxide)
RN  - K2I13DR72L (Gadolinium DTPA)
SB  - IM
MH  - Animals
MH  - Brain/metabolism/pathology
MH  - Contrast Media
MH  - Disease Models, Animal
MH  - Disease Progression
MH  - Encephalomyelitis, Autoimmune, Experimental/*diagnosis/*metabolism
MH  - Endothelium/metabolism/pathology
MH  - Female
MH  - Ferric Compounds
MH  - Gadolinium DTPA
MH  - Humans
MH  - Immunohistochemistry
MH  - Magnetic Resonance Imaging/*methods
MH  - Mice
MH  - Multiple Sclerosis/*diagnosis/*metabolism
MH  - Translational Research, Biomedical
MH  - Vascular Cell Adhesion Molecule-1/*metabolism
PMC - PMC3394669
MID - UKMS47719
OID - NLM: UKMS47719
EDAT- 2011/09/13 06:00
MHDA- 2012/03/01 06:00
PMCR- 2012/07/11
CRDT- 2011/09/13 06:00
PHST- 2011/09/13 06:00 [entrez]
PHST- 2011/09/13 06:00 [pubmed]
PHST- 2012/03/01 06:00 [medline]
PHST- 2012/07/11 00:00 [pmc-release]
AID - fj.11-183772 [pii]
AID - 10.1096/fj.11-183772 [doi]
PST - ppublish
SO  - FASEB J. 2011 Dec;25(12):4415-22. doi: 10.1096/fj.11-183772. Epub 2011 Sep 9.